Core Viewpoint - Real Bio Technology Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange for the third time, with China International Capital Corporation as its sole sponsor [1]. Company Overview - Real Bio, established in 2012, focuses on the innovative research and development of drugs for viral infections, tumors, and cardiovascular diseases. The company has developed a comprehensive drug portfolio, including five candidate drugs, with its core product, Azvudine, conditionally approved in China for treating HIV and COVID-19 [5][6]. Product Pipeline - The core product Azvudine is a Class 1 innovative drug that received conditional approval from the National Medical Products Administration (NMPA) for HIV treatment in July 2021 and for COVID-19 in July 2022. It is the first oral antiviral drug developed by a Chinese company approved for COVID-19 treatment [6]. - The company also has a strong pipeline for cancer treatment, with Azvudine showing broad-spectrum anti-tumor activity and being the only nucleoside anti-tumor drug with dual mechanisms and high selectivity in the past 30 years [6]. Production and Commercialization - Real Bio has established its own production facilities with an annual capacity of approximately 3 billion tablets, certified by GMP, to meet existing commercialization needs. The company has a professional commercialization team and a complete management system [7]. - Azvudine was included in the National Reimbursement Drug List (NRDL) in 2023 and successfully renewed its inclusion in 2024, ensuring price stability and broad market access [7]. Financial Performance - The company reported revenues of RMB 344.21 million, RMB 237.87 million, and RMB 16.53 million for the fiscal years ending December 31, 2023, 2024, and the six months ending June 30, 2025, respectively. All revenue during the reporting period came from Azvudine [11]. - The company recorded a gross loss of RMB 329.41 million, a gross profit of RMB 164.85 million, and a gross loss of RMB 43.42 million for the same periods [12]. - The net losses for the fiscal years were RMB 783.58 million, RMB 40.04 million, and RMB 165.43 million, primarily due to significant R&D expenses for core products and other candidates [13]. Market Overview - The global antiviral drug market was valued at USD 73.6 billion in 2023, with a compound annual growth rate (CAGR) of 6.3% from 2018 to 2023, expected to reach USD 101.1 billion by 2030 [14]. - The Chinese antiviral drug market grew from USD 3.5 billion in 2018 to USD 7.8 billion in 2023, with a CAGR of 17.1%, projected to reach USD 21.8 billion by 2030 [16]. HIV Drug Market - The global HIV drug market increased from USD 35.3 billion in 2018 to USD 43.1 billion in 2023, with a CAGR of 4.1%, expected to reach USD 59.5 billion by 2030 [20]. - In China, the HIV drug market grew from USD 304.5 million in 2018 to USD 636.2 million in 2023, with a CAGR of 15.9%, projected to reach USD 2.33 billion by 2030 [21]. Oncology Drug Market - The global oncology drug market expanded from USD 128.1 billion in 2018 to USD 228.9 billion in 2023, with a CAGR of 12.3%, expected to reach USD 419.8 billion by 2030 [25]. - The Chinese oncology drug market increased from USD 23.8 billion in 2023 to USD 34.1 billion, with a CAGR of 7.2%, projected to reach USD 77.5 billion by 2030 [28].
新股消息 | 真实生物三度递表港交所 核心产品阿兹夫定在中国获附条件批准用于治疗HIV感染及COVID-19
Zhi Tong Cai Jing·2025-11-09 23:57